Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisi, Alessandro, Cortellini, Alessio, Cannita, Katia, Bersanelli, Melissa, Ficorella, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387689/
https://www.ncbi.nlm.nih.gov/pubmed/30881713
http://dx.doi.org/10.1155/2019/3452762
_version_ 1783397622980018176
author Parisi, Alessandro
Cortellini, Alessio
Cannita, Katia
Bersanelli, Melissa
Ficorella, Corrado
author_facet Parisi, Alessandro
Cortellini, Alessio
Cannita, Katia
Bersanelli, Melissa
Ficorella, Corrado
author_sort Parisi, Alessandro
collection PubMed
description Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of PD-L1 inhibitors in this population. Here, we report the first case of a male patient with metastatic urothelial cell carcinoma and ESRD on dialysis, safely treated with atezolizumab.
format Online
Article
Text
id pubmed-6387689
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-63876892019-03-17 Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis Parisi, Alessandro Cortellini, Alessio Cannita, Katia Bersanelli, Melissa Ficorella, Corrado Case Rep Oncol Med Case Report Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of PD-L1 inhibitors in this population. Here, we report the first case of a male patient with metastatic urothelial cell carcinoma and ESRD on dialysis, safely treated with atezolizumab. Hindawi 2019-02-10 /pmc/articles/PMC6387689/ /pubmed/30881713 http://dx.doi.org/10.1155/2019/3452762 Text en Copyright © 2019 Alessandro Parisi et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Parisi, Alessandro
Cortellini, Alessio
Cannita, Katia
Bersanelli, Melissa
Ficorella, Corrado
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
title Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
title_full Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
title_fullStr Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
title_full_unstemmed Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
title_short Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
title_sort safe administration of anti-pd-l1 atezolizumab in a patient with metastatic urothelial cell carcinoma and end-stage renal disease on dialysis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387689/
https://www.ncbi.nlm.nih.gov/pubmed/30881713
http://dx.doi.org/10.1155/2019/3452762
work_keys_str_mv AT parisialessandro safeadministrationofantipdl1atezolizumabinapatientwithmetastaticurothelialcellcarcinomaandendstagerenaldiseaseondialysis
AT cortellinialessio safeadministrationofantipdl1atezolizumabinapatientwithmetastaticurothelialcellcarcinomaandendstagerenaldiseaseondialysis
AT cannitakatia safeadministrationofantipdl1atezolizumabinapatientwithmetastaticurothelialcellcarcinomaandendstagerenaldiseaseondialysis
AT bersanellimelissa safeadministrationofantipdl1atezolizumabinapatientwithmetastaticurothelialcellcarcinomaandendstagerenaldiseaseondialysis
AT ficorellacorrado safeadministrationofantipdl1atezolizumabinapatientwithmetastaticurothelialcellcarcinomaandendstagerenaldiseaseondialysis

Ejemplares similares